Immunomedics says new data for lead drug IMMU-132 in triple-negative breast cancer keep it on course to file for accelerated approval in mid-2017.

NYSE-listed small cap PharmAthene and private infectious disease biotech Altimmune have signed a merger pact that will see the pair become one in an all-stock…

Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO.

Eli Lilly says it will spend nearly $1 billion to buy out CoLucid Pharmaceuticals and get its hands on its late-stage acute migraine candidate, and is a case…

A phase 2 trial of Neurocrine’s Ingrezza in Tourette syndrome has missed its primary endpoint.

Women’s health biotech ObsEva has set the terms for an IPO that could net it in the region of $87 million.

AstraZeneca has pushed back the estimated completion date for the phase 3 trial of its PD-L1 drug, a first-line treatment for non-small cell lung cancer.

Alcobra took a body blow last year when the FDA placed a clinical hold on its lead drug metadoxine, but a failed phase 3 trial has now delivered a coup de…

R&D